CN109142757A - A kind of brucella indirect ELISA testing kit - Google Patents
A kind of brucella indirect ELISA testing kit Download PDFInfo
- Publication number
- CN109142757A CN109142757A CN201811301269.8A CN201811301269A CN109142757A CN 109142757 A CN109142757 A CN 109142757A CN 201811301269 A CN201811301269 A CN 201811301269A CN 109142757 A CN109142757 A CN 109142757A
- Authority
- CN
- China
- Prior art keywords
- brucella
- serum
- indirect elisa
- wzt
- dilution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000589562 Brucella Species 0.000 title claims abstract description 48
- 238000002965 ELISA Methods 0.000 title claims abstract description 40
- 238000012360 testing method Methods 0.000 title claims description 40
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 22
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 22
- 238000000576 coating method Methods 0.000 claims abstract description 20
- 239000000427 antigen Substances 0.000 claims abstract description 17
- 102000036639 antigens Human genes 0.000 claims abstract description 17
- 108091007433 antigens Proteins 0.000 claims abstract description 17
- 239000011248 coating agent Substances 0.000 claims abstract description 16
- 238000001514 detection method Methods 0.000 claims abstract description 14
- 210000002966 serum Anatomy 0.000 claims description 73
- 238000010790 dilution Methods 0.000 claims description 35
- 239000012895 dilution Substances 0.000 claims description 35
- 102000004190 Enzymes Human genes 0.000 claims description 20
- 108090000790 Enzymes Proteins 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 239000005018 casein Substances 0.000 claims description 13
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 13
- 235000021240 caseins Nutrition 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000000872 buffer Substances 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 238000005215 recombination Methods 0.000 claims description 9
- 230000006798 recombination Effects 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 8
- 239000013612 plasmid Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 17
- 238000005259 measurement Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 206010006500 Brucellosis Diseases 0.000 description 7
- 241001494479 Pecora Species 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000003252 repetitive effect Effects 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 238000010828 elution Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000607734 Yersinia <bacteria> Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- PIPTUBPKYFRLCP-NHCYSSNCSA-N Ala-Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PIPTUBPKYFRLCP-NHCYSSNCSA-N 0.000 description 1
- ZIWWTZWAKYBUOB-CIUDSAMLSA-N Ala-Asp-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O ZIWWTZWAKYBUOB-CIUDSAMLSA-N 0.000 description 1
- ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 1
- MPLOSMWGDNJSEV-WHFBIAKZSA-N Ala-Gly-Asp Chemical compound [H]N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MPLOSMWGDNJSEV-WHFBIAKZSA-N 0.000 description 1
- PNALXAODQKTNLV-JBDRJPRFSA-N Ala-Ile-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O PNALXAODQKTNLV-JBDRJPRFSA-N 0.000 description 1
- DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 description 1
- NHWYNIZWLJYZAG-XVYDVKMFSA-N Ala-Ser-His Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N NHWYNIZWLJYZAG-XVYDVKMFSA-N 0.000 description 1
- UISQLSIBJKEJSS-GUBZILKMSA-N Arg-Arg-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(O)=O UISQLSIBJKEJSS-GUBZILKMSA-N 0.000 description 1
- RKRSYHCNPFGMTA-CIUDSAMLSA-N Arg-Glu-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O RKRSYHCNPFGMTA-CIUDSAMLSA-N 0.000 description 1
- OQCWXQJLCDPRHV-UWVGGRQHSA-N Arg-Gly-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O OQCWXQJLCDPRHV-UWVGGRQHSA-N 0.000 description 1
- KMFPQTITXUKJOV-DCAQKATOSA-N Arg-Ser-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O KMFPQTITXUKJOV-DCAQKATOSA-N 0.000 description 1
- OQPAZKMGCWPERI-GUBZILKMSA-N Arg-Ser-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OQPAZKMGCWPERI-GUBZILKMSA-N 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- CTQIOCMSIJATNX-WHFBIAKZSA-N Asn-Gly-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O CTQIOCMSIJATNX-WHFBIAKZSA-N 0.000 description 1
- XVBDDUPJVQXDSI-PEFMBERDSA-N Asn-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N XVBDDUPJVQXDSI-PEFMBERDSA-N 0.000 description 1
- XLDMSQYOYXINSZ-QXEWZRGKSA-N Asn-Val-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N XLDMSQYOYXINSZ-QXEWZRGKSA-N 0.000 description 1
- XZFONYMRYTVLPL-NHCYSSNCSA-N Asn-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC(=O)N)N XZFONYMRYTVLPL-NHCYSSNCSA-N 0.000 description 1
- KVMPVNGOKHTUHZ-GCJQMDKQSA-N Asp-Ala-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KVMPVNGOKHTUHZ-GCJQMDKQSA-N 0.000 description 1
- VILLWIDTHYPSLC-PEFMBERDSA-N Asp-Glu-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VILLWIDTHYPSLC-PEFMBERDSA-N 0.000 description 1
- MFTVXYMXSAQZNL-DJFWLOJKSA-N Asp-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC(=O)O)N MFTVXYMXSAQZNL-DJFWLOJKSA-N 0.000 description 1
- JNNVNVRBYUJYGS-CIUDSAMLSA-N Asp-Leu-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O JNNVNVRBYUJYGS-CIUDSAMLSA-N 0.000 description 1
- PCJOFZYFFMBZKC-PCBIJLKTSA-N Asp-Phe-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O PCJOFZYFFMBZKC-PCBIJLKTSA-N 0.000 description 1
- VHUKCUHLFMRHOD-MELADBBJSA-N Asp-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)O)N)C(=O)O VHUKCUHLFMRHOD-MELADBBJSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001148106 Brucella melitensis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 101100256910 Drosophila melanogaster sick gene Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- HHQCBFGKQDMWSP-GUBZILKMSA-N Gln-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HHQCBFGKQDMWSP-GUBZILKMSA-N 0.000 description 1
- VGUYMZGLJUJRBV-YVNDNENWSA-N Glu-Ile-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O VGUYMZGLJUJRBV-YVNDNENWSA-N 0.000 description 1
- CCBIBMKQNXHNIN-ZETCQYMHSA-N Gly-Leu-Gly Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CCBIBMKQNXHNIN-ZETCQYMHSA-N 0.000 description 1
- AFWYPMDMDYCKMD-KBPBESRZSA-N Gly-Leu-Tyr Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AFWYPMDMDYCKMD-KBPBESRZSA-N 0.000 description 1
- NTBOEZICHOSJEE-YUMQZZPRSA-N Gly-Lys-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O NTBOEZICHOSJEE-YUMQZZPRSA-N 0.000 description 1
- IFHJOBKVXBESRE-YUMQZZPRSA-N Gly-Met-Gln Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)CN IFHJOBKVXBESRE-YUMQZZPRSA-N 0.000 description 1
- HHRODZSXDXMUHS-LURJTMIESA-N Gly-Met-Gly Chemical compound CSCC[C@H](NC(=O)C[NH3+])C(=O)NCC([O-])=O HHRODZSXDXMUHS-LURJTMIESA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- OVPYIUNCVSOVNF-ZPFDUUQYSA-N Ile-Gln-Pro Natural products CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O OVPYIUNCVSOVNF-ZPFDUUQYSA-N 0.000 description 1
- FUOYNOXRWPJPAN-QEWYBTABSA-N Ile-Glu-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N FUOYNOXRWPJPAN-QEWYBTABSA-N 0.000 description 1
- KIAOPHMUNPPGEN-PEXQALLHSA-N Ile-Gly-His Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KIAOPHMUNPPGEN-PEXQALLHSA-N 0.000 description 1
- PWUMCBLVWPCKNO-MGHWNKPDSA-N Ile-Leu-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PWUMCBLVWPCKNO-MGHWNKPDSA-N 0.000 description 1
- CKRFDMPBSWYOBT-PPCPHDFISA-N Ile-Lys-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N CKRFDMPBSWYOBT-PPCPHDFISA-N 0.000 description 1
- RVNOXPZHMUWCLW-GMOBBJLQSA-N Ile-Met-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)N)C(=O)O)N RVNOXPZHMUWCLW-GMOBBJLQSA-N 0.000 description 1
- SNHYFFQZRFIRHO-CYDGBPFRSA-N Ile-Met-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)O)N SNHYFFQZRFIRHO-CYDGBPFRSA-N 0.000 description 1
- ZDNNDIJTUHQCAM-MXAVVETBSA-N Ile-Ser-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N ZDNNDIJTUHQCAM-MXAVVETBSA-N 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 1
- ILJREDZFPHTUIE-GUBZILKMSA-N Leu-Asp-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ILJREDZFPHTUIE-GUBZILKMSA-N 0.000 description 1
- HMDDEJADNKQTBR-BZSNNMDCSA-N Leu-His-Tyr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O HMDDEJADNKQTBR-BZSNNMDCSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- LZHJZLHSRGWBBE-IHRRRGAJSA-N Leu-Lys-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LZHJZLHSRGWBBE-IHRRRGAJSA-N 0.000 description 1
- GOFJOGXGMPHOGL-DCAQKATOSA-N Leu-Ser-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(C)C GOFJOGXGMPHOGL-DCAQKATOSA-N 0.000 description 1
- KLSUAWUZBMAZCL-RHYQMDGZSA-N Leu-Thr-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(O)=O KLSUAWUZBMAZCL-RHYQMDGZSA-N 0.000 description 1
- RVOMPSJXSRPFJT-DCAQKATOSA-N Lys-Ala-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RVOMPSJXSRPFJT-DCAQKATOSA-N 0.000 description 1
- PNPYKQFJGRFYJE-GUBZILKMSA-N Lys-Ala-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNPYKQFJGRFYJE-GUBZILKMSA-N 0.000 description 1
- DLCAXBGXGOVUCD-PPCPHDFISA-N Lys-Thr-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DLCAXBGXGOVUCD-PPCPHDFISA-N 0.000 description 1
- RPWTZTBIFGENIA-VOAKCMCISA-N Lys-Thr-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O RPWTZTBIFGENIA-VOAKCMCISA-N 0.000 description 1
- RVYDCISQIGHAFC-ZPFDUUQYSA-N Met-Ile-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O RVYDCISQIGHAFC-ZPFDUUQYSA-N 0.000 description 1
- IHRFZLQEQVHXFA-RHYQMDGZSA-N Met-Thr-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCCN IHRFZLQEQVHXFA-RHYQMDGZSA-N 0.000 description 1
- FSTWDRPCQQUJIT-NHCYSSNCSA-N Met-Val-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCSC)N FSTWDRPCQQUJIT-NHCYSSNCSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- IUVYJBMTHARMIP-PCBIJLKTSA-N Phe-Asp-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O IUVYJBMTHARMIP-PCBIJLKTSA-N 0.000 description 1
- CSDMCMITJLKBAH-SOUVJXGZSA-N Phe-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O CSDMCMITJLKBAH-SOUVJXGZSA-N 0.000 description 1
- WLYPRKLMRIYGPP-JYJNAYRXSA-N Phe-Lys-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 WLYPRKLMRIYGPP-JYJNAYRXSA-N 0.000 description 1
- IEOHQGFKHXUALJ-JYJNAYRXSA-N Phe-Met-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IEOHQGFKHXUALJ-JYJNAYRXSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- UREQLMJCKFLLHM-NAKRPEOUSA-N Pro-Ile-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UREQLMJCKFLLHM-NAKRPEOUSA-N 0.000 description 1
- ITUDDXVFGFEKPD-NAKRPEOUSA-N Pro-Ser-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ITUDDXVFGFEKPD-NAKRPEOUSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- CAGTXGDOIFXLPC-KZVJFYERSA-N Thr-Arg-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CCCN=C(N)N CAGTXGDOIFXLPC-KZVJFYERSA-N 0.000 description 1
- KBBRNEDOYWMIJP-KYNKHSRBSA-N Thr-Gly-Thr Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KBBRNEDOYWMIJP-KYNKHSRBSA-N 0.000 description 1
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 1
- WNQJTLATMXYSEL-OEAJRASXSA-N Thr-Phe-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WNQJTLATMXYSEL-OEAJRASXSA-N 0.000 description 1
- SCCKSNREWHMKOJ-SRVKXCTJSA-N Tyr-Asn-Ser Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O SCCKSNREWHMKOJ-SRVKXCTJSA-N 0.000 description 1
- VYQQQIRHIFALGE-UWJYBYFXSA-N Tyr-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VYQQQIRHIFALGE-UWJYBYFXSA-N 0.000 description 1
- QPZMOUMNTGTEFR-ZKWXMUAHSA-N Val-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N QPZMOUMNTGTEFR-ZKWXMUAHSA-N 0.000 description 1
- UKEVLVBHRKWECS-LSJOCFKGSA-N Val-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)N UKEVLVBHRKWECS-LSJOCFKGSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940038698 brucella melitensis Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010040030 histidinoalanine Proteins 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 108010015796 prolylisoleucine Proteins 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明提供一种布鲁氏菌间接ELISA检测试剂盒,所述试剂盒以布鲁氏菌wzt重组蛋白为包被抗原。本发明的试剂盒能够高敏感以及高特异的检测布鲁氏菌,能够用于布鲁氏菌的诊断和科学研究。
The invention provides a Brucella indirect ELISA detection kit, which uses the Brucella wzt recombinant protein as a coating antigen. The kit of the invention can detect Brucella with high sensitivity and high specificity, and can be used for the diagnosis and scientific research of Brucella.
Description
Technical field
The invention belongs to technique for gene engineerings and diagnostic reagent technical field, and in particular to a kind of brucella is indirect
ELISA detection kit.
Background technique
Brucellosis is the zoonosis that one kind as caused by brucella can infect people and domestic animal, master in domestic animal
Infected cattle, sheep, pig, dog are wanted, wherein the infection conditions of ox and sheep are the most serious, and animal suffering from disease can cause pregnant animal miscarriage, produce
The symptoms such as milk decline, infertility, people's illness will appear the symptoms such as the tired, fever of arthralgia, whole body.Brucellosis is broadcast to
Animal husbandry and human health bring very big harm, and the annual new infections number in the whole world is about 500,000 people, except a small number of flourishing
It is national outer, with the presence of more than 170 a country's brucellosis.Infecting brucellosis is mainly and infected animal especially illness
Animal pregnancy, unprocessed meat products or dairy products contact.
The pathogenic mechanism of brucella is their ability to survive in host's mononuclear macrophage, though hypoxemia, nutrition not
Foot, acidic environment and there are remain to survive under conditions of oxide.And brucella is bacterial parasite intracellular, once infection is difficult
To pass through antibiotic treatment.Even if infection animal self-healing still has the danger of lasting discharge of bacteria.
In terms of brucellosis diagnosis, ELISA kit have high sensitivity, high specificity, stability is good, operation is simple
Single, result is easy to the advantages that determining.
Summary of the invention
The purpose of the present invention is to provide a kind of brucella indirect ELISA testing kits, can be used in brucella
The qualitative detection of sick antibody has the advantages that high specificity, sensibility are high, reproducible, easily operated.
The present invention provides a kind of brucella indirect ELISA testing kit, and the kit is with brucella wzt recombination
Albumen is envelope antigen.
Preferably, the amino acid sequence of the recombinant protein is SEQ ID No.2 in sequence table.
Preferably, the recombinant protein the preparation method comprises the following steps: by brucella wzt gene fragment clone to pET30a
At the multiple cloning sites of (+) expression vector, recombinant plasmid pET-30a-wzt is obtained, recombinant plasmid pET-30a-wzt is transformed into
Inducing expression is carried out in e. coli bl21 competent cell, is collected supernatant and is purified, obtains recombinant protein after purification.
Preferably, the kit further includes confining liquid, the confining liquid is Casein.
Preferably, the kit further includes coating buffer, the carbon that the coating buffer is 0.025M pH9.6
Phthalate buffer.
Preferably, the kit further includes serum dilution, the serum dilution is Casein.
Preferably, the kit further includes ELIAS secondary antibody, the ELIAS secondary antibody is horseradish peroxidase-labeled
The anti-sheep IgG enzyme labelled antibody of mouse.
The present invention also provides application of the mentioned reagent box in detection brucella, the application not with the diagnosis of disease and
For the purpose for the treatment of.
The present invention also provides the indirect ELISA detection method of above-mentioned brucella, the detection method not examining with disease
For the purpose of disconnected and treatment, steps are as follows:
(1) coated elisa plate: by pET-30a-wzt recombinant protein described in claim any one of 1-3 after purification
It is coated with microwell plate;Peridium concentration is 15 μ g/mL;Coating condition is that 4 DEG C of coatings are stayed overnight;
(2) ELISA Plate is closed;The confining liquid being closed as when 37 DEG C of closing 3h, closing is Casein;
(3) serum to be checked after dilution is added, in 37 DEG C of reaction 1h;It is described to be diluted to serum serum dilution to be checked
It is diluted with 1:80;
(4) ELIAS secondary antibody after dilution is added, in 37 DEG C of reaction 30min or 90min;It is described to be diluted to use ELIAS secondary antibody
ELIAS secondary antibody dilution is diluted with 1:5000;
(5) it develops the color, terminates, and read OD in microplate reader450Nm value.
The detection brucella that kit of the invention can be high sensitive and height is special, it is anti-to can be used in brucellosis
The qualitative detection of body has the advantages that high specificity, sensibility are high, reproducible, easily operated.It can also be used to brucella
Diagnosis and scientific research.
Detailed description of the invention
Attached drawing is used to provide further understanding of the present invention, and constitutes part of specification, with reality of the invention
It applies example to be used to explain the present invention together, not be construed as limiting the invention.In the accompanying drawings:
Fig. 1 is unpurified brucella wzt recombinant protein SDS-PAGE electrophoresis provided in an embodiment of the present invention.
Fig. 2 is the brucella wzt recombinant protein SDS-PAGE electrophoresis of purifying provided in an embodiment of the present invention.
Specific embodiment
Embodiment below facilitates a better understanding of the present invention, but does not limit the present invention.Experiment in following embodiments
Method is unless otherwise specified conventional method.Test material as used in the following examples is unless otherwise specified certainly
What routine biochemistry reagent shop was commercially available.
Embodiment 1
1, experiment reagent and instrument
Reagent: serum;Serum dilution, serum dilution are casein (SIGMA company);The anti-sheep IgG- horseradish peroxide of mouse
Compound enzyme conjugates;It is coated with buffer;Cleaning solution, cleaning solution are the phosphate buffer of 0.5 ‰ Tween-20 containing mass fraction;
Block buffer is casein (SIGMA company);Substrate developing solution is that every 500mL adds disodium ethylene diamine tetraacetate 0.2g, lemon
Sour 0.95g, glycerol 50mL and TMB powder 0.15g;Terminate liquid is the sulfuric acid solution of 2mol/L.
Instrument: enzyme-linked immunosorbent assay instrument, single track pipettor, 8 Dao Huo, 12 pipettor, sample injector, board-washing machine etc..
Consumptive material: ELISA micro-reaction plate selects the micro ELISA Plate of 96 hole polystyrenes;Serum dilutes plate, suction pipette head
Deng.
2, the preparation of brucella wzt recombinant protein indirect ELISA testing kit
The expression and purification of 2.1 brucella wzt recombinant proteins
Lipopolysaccharides is the Major Virulence Factors of brucella, to the integrality of the structure and function of Gram-negative bacteria outer membrane
It is most important.Wherein, wzt gene is the chief component of abc transport system, while being the synthesis key gene of LPS again.It grinds
Study carefully discovery, the missing of the gene will cause the biosynthesis block of LPS.Use individual gene wzt in LPS as antigen compared to
LPS is that antigentic specificity can be higher, avoids cross reaction.
PCR amplification wzt genetic fragment first, then using EcoR I and SalI while digestion PCR product and expression vector
PET-30a is attached after glue recycling target fragment and carrier, construction recombination plasmid, then by recombinant plasmid transformed to competence
E. coli bl21 (DE3) pLys cell, through IPTG inducing expression, the condition of inducing expression are as follows: 25 DEG C of shaking table 180rpm inductions
5h takes supernatant to carry out SDS-PAGE electrophoretic analysis, and pre- as a result as shown in Figure 1, occurring specific band at about 30kDa
Phase is consistent, and electrophoretic analysis result prompt destination protein is mainly expressed with soluble form.Recombinant protein through Ni-NTA after purification, it is pure
Degree is up to 90% or more, as shown in Figure 2.The nucleotide sequence and amino acid sequence of recombinant protein are respectively as follows:
The amino acid sequence of recombinant protein are as follows:
MIQPSITLSNVHLHYAASAFKERSVKTLVNALLSMRRSAGANIEDIHALKGISVDIARGERVALIGHNG
AGKSTFLKTIAGLYPISSGTLKVTGTVRSLFDIGLGFEPDATGRENILYRGLLLGLTPRFMREIEDEIIEFADLGDF
IDYPIKTYSAGMQVRLAFAISTAVDGDILLLDEVIGAGDAAFMTKAKARIMNMVEKAEIMVLASHDLANVRQLCTRA
LVFKAGTIAFDGRVEDAISFYNSGMGAIA
Wherein, PCR amplification wzt genetic fragment method particularly includes:
Design primer
Upstream primer:
5'-CCGGAATTCGCCACCATGATCCAGCCATCGATTACCCT-3';
Downstream primer:
5'-CCGGTCGACTTAATGATGATGATGATGATGTGCTATAGCTCCCATTCCCG-3';
PCR reaction system: each 2 μ L of 2 μ L of template, upstream and downstream primer, 25 μ L of Taq Mastermix enzyme, dd H2O 19μL。
Wherein, Taq Mastermix enzyme is purchased from TaKaRa company.
Using brucella genome as the PCR reaction condition of template are as follows: 95 DEG C of initial denaturation 5min, 94 DEG C of denaturation 40s, 55 DEG C
Anneal 40s, and 72 DEG C of extension 2min, 72 DEG C extend 10min eventually.
Wherein, the purification process of recombinant protein specifically:
Collect thallus, ultrasound after 4 DEG C, 8000rpm be centrifuged 45min, then use His Trap FF affinity chromatography column purification egg
It is white, it is operated according to the step of balance, upper albumen, elution foreign protein, elution destination protein.Elute foreign protein and elution purpose
Albumen is using imidazole solution, wherein the concentration for eluting the imidazole solution of foreign protein is 40mM, elutes the imidazoles of destination protein
The concentration of solution is 250mM.
Fig. 1 is unpurified brucella wzt recombinant protein SDS-PAGE electrophoresis provided in an embodiment of the present invention;Figure
In, M: Protein Marker;1,3: other albumen of expression;2: recombination wzt albumen, arrow meaning are recombinant protein.
Fig. 2 is the brucella wzt recombinant protein SDS-PAGE electrophoresis of purifying provided in an embodiment of the present invention;In figure,
M: Protein Marker;1,2: elution albumen, arrow meaning are recombinant protein.
The determination of the best peridium concentration of 2.2 antigens
It is using recombinant protein wzt obtained in step 2.1 as envelope antigen, envelope antigen is dilute with coating buffer multiple proportions
It is interpreted into 30 μ g/mL, 15 μ g/mL, 7.5 μ g/mL, 3.75 μ g/mL, 1.875 μ g/mL and 0.9375 μ g/mL, each hole of ELISA Plate adds
Enter 100 μ L, i.e., each final antigen total amount in hole is followed successively by 3 holes μ g/, 1.5 holes μ g/, 0.75 hole μ g/, 0.375 hole μ g/, 0.1875
The hole μ g/ and 0.09375 hole μ g/.
With 96 hole elisa Plates are coated with after coating buffer dilution, 4 DEG C of coatings are gone to overnight after setting 37 DEG C of incubation 2h.With
Cleaning solution is washed 3 times and is patted dry, and 200 μ L of confining liquid is added in 37 DEG C of closing 2h, washing.By 2 parts of negative serums (being denoted as N1 and N2)
After being serially diluted respectively with serum dilution with 1:100 with 4 parts of positive serums (being denoted as P1, P2, P3 and P4), every hole is added
100 μ L, every part of serum are loaded twice under same antigen coat concentration conditions, i.e., multiple holes are loaded;Then 37 DEG C of reaction 1h, washing
It pats dry for 3 times, 100 μ L ELIAS secondary antibody (extension rate 1:10000), 37 DEG C of reaction 1h are added in every hole;It washs 3 times and pats dry.TMB is added
100 hole μ L/ of substrate developing solution, 37 DEG C are protected from light 15min, and 2mol/L H then is added with the amount in 50 holes μ L/2SO4It terminates anti-
It answers, sets enzyme mark detector measurement OD450Nm value, measurement result are as shown in table 1 below.
1 antigen coat concentration screening result of table
By the experimental data measured in table 1, Computation immunity goat-anti serum (i.e. positive serum) is with respect to OD450Nm value and yin
Property control serum is with respect to OD450Nm value, i.e. P/N value select relatively large 15 μ g/mL of antigen coat concentration (the 1.5 μ g/ of P/N value
Hole) it is best peridium concentration.
The determination of 2.3 antigen coat optimum conditions
Brucella recombinant antigen wzt albumen coating is carried out according to the peridium concentration of 2.2 selections, coating plate is respectively placed in
It is coated under 3 conditionals below: (1) 37 DEG C of 2h;(2) 4 DEG C overnight;It is stayed overnight for 4 DEG C after (3) 37 DEG C of 2h.Positive serum is sheep cloth Lu Shi
Bacterium positive serum, negative serum is Brucella melitensis negative serum, right respectively by 2.2 method for coating and best peridium concentration
It is carried out using the 2 parts of negative serums (being denoted as N1 and N2) and 4 parts of positive serums (being denoted as P1, P2, P3 and P4) of above-mentioned coating condition
ELISA test, each sample are repeated 2 times, and measure each hole OD450Nm value, measurement result are as shown in table 2 below.
2 antigen coat optimum condition of table
P/N value is calculated, as shown in Table 2, it is maximum that the P/N value measured overnight is closed under the conditions of 4 DEG C, therefore selects 4 DEG C to stay overnight
It is closed as antigen coat optimum condition.
The determination of 2.4 serum optimum dilution degrees
4 parts of positive serums (P1, P2, P3 are diluted with dilution 1:25,1:50,1:100,1:200 respectively with serum dilution
And P4) and 2 parts of negative serums (N1 and N2) be primary antibody.ELISA test is carried out according to 2.2 method, each sample repeats 2
It is secondary, measure each hole OD450Nm value, measurement result are as shown in table 3.
The selection of the best serum dilution of table 3
Calculate P/N value, as shown in Table 3, the serum dilution of reacting hole when P/N value is larger as best operating condition,
Determine that serum optimum dilution degree is 1:80 on this basis.
The selection of 2.5 confining liquids and sealing condition
(1) selection of confining liquid: select containing mass fraction be respectively 5% skimmed milk power, 10% skimmed milk power, 5%BSA,
The PBS confining liquid of 10%BSA and from SIGMA company buy confining liquid (Casein) closed, according to 2.3 determine most
Good sealing condition is closed, and the serum optimum diluting multiple determined by 2.4 is to 2 parts of negative serums (being denoted as N1 and N2) and 5 parts
Positive serum (being denoted as P1, P2, P3, P4 and P5) dilution, each sample are repeated 2 times, other ELISA measuring methods are measured with 2.2
Each hole OD450Nm value, measurement result are as shown in table 4.
The best confining liquid the selection result of table 4
P/N value is calculated, the results are shown in Table 4, it is known that the P/N value of the closed elisa plate of confining liquid Casein is maximum, determines that it is
Best confining liquid.
(2) it the selection of best off-period: with most suitable antigen concentration coated elisa plate, is carried out with selected best confining liquid
Closing, off-period are respectively 1h, 2h and 3h, and the serum optimum diluting multiple that then positive serum is determined by 2.4 dilutes, each
Sample is repeated 2 times, other ELISA measuring methods are the same as 2.2.Measure each hole OD450Nm value, measurement result are as shown in table 5.
The best off-period the selection result of table 5
Compare the OD of each group negative serum and positive serum450Nm value calculates P/N value, as shown in Table 5 in 37 DEG C of temperature
The P/N value that lower closing 3h is measured is maximum, therefore selects 37 DEG C of 3h for best sealing condition.
The determination of 2.6 blood serum sample optimum reacting times
On the basis of the optimum test condition measured above, the optimum reacting time of blood serum sample is screened, is added
After entering serum, respectively in 37 DEG C of reactions 15min, 30min, 60min, 90min, by 2.2 method to 2 parts of negative serum (N1
And N2) and 5 parts of positive serums (P1, P2, P3, P4 and P5) carry out ELISA tests, each sample is repeated 3 times, and measures each hole
OD450Nm value, measurement result are as shown in table 6.
The screening of 6 blood serum sample optimum reacting time of table
Calculate P/N value, as shown in Table 6, the P/N value highest that seroreaction 60min is measured, it is thus determined that under the conditions of 37 DEG C
Seroreaction Best Times are 60min.
2.7 enzymes mark conjugate optimum dilution degree and the determination in reaction time
(1) on the basis of the optimum test condition measured above, to enzyme label optimum dilution degree and the reaction time into
Row screening.By enzyme labelled antibody by extension rate be respectively 1:5000,1:10000,1:15000 dilution, then in 37 DEG C respectively temperature
30min is educated, other operating procedures carry out ELISA test, each sample to 2 parts of negative serums, 5 parts of positive serums by 2.2 method
It is repeated 3 times, measures each hole OD450nm value, measurement result is as shown in table 7.
7 enzyme of table marks the screening of conjugate optimum dilution degree
P/N value and average P/N value are calculated, table 7 shows enzyme label conjugate in 1:5000 dilution times, and P/N value reaches most
Greatly, so 1:5000 is that enzyme marks conjugate optimum dilution degree.
(2) after being diluted according to enzyme conjugates optimum dilution degree screen in 2.7 (1), in 37 DEG C respectively incubation 30min,
60min, 90min carry out 2 parts of negative serums (N1, N2) and 5 parts of positive serums (P1, P2, P3, P4 and P5) by 2.2 method
ELISA test, each sample are repeated 2 times, and measure each hole OD450Nm value, measurement result are as shown in table 8.
The screening of 8 enzyme of table label conjugate optimum reacting time
Calculate negative average value, positive average value and average P/N value, as shown in Table 8 enzyme mark conjugate effect 30min when with
P/N value difference is not little when 90min, to keep convenient experimental operation quick, therefore, when 30min being selected to act on for best enzyme labelled antibody
Between.
The optimum reacting time of 2.8 substrates
On the basis of the optimum test condition measured above, enzyme labelled antibody by the aforementioned time effect optimized, washing,
5min, 10min, 15min and 30min, the method that other operating procedures press 2.2 are reacted respectively in 37 DEG C after substrate developing solution is added
ELISA test is carried out to 6 parts of negative serums and 6 parts of positive serums, each sample is repeated 2 times, and measures each hole OD450Nm value, measurement
The results are shown in Table 9.
The optimum reacting time of 9 substrate of table screens
P/N value is calculated, the results are shown in Table 9, P/N value highest when substrate reactions 15min, therefore the selected 15min of selected substrate is
Optimum reacting time.
The foundation of 2.9 brucella indirect ELISA testing kits
(1) ELISA Plate of pre-coated brucella wzt recombinant protein of the invention;
(2) it is coated with buffer: the carbonate buffer solution of 0.025M pH9.6: Na2CO3 0.4779g,
NaHCO30.4620g, distilled water are settled to 100mL after completely dissolution;
(3) confining liquid: Casein (SIGMA company, article No. are as follows: B6429);
(4) serum dilution: Casein (SIGMA company, article No. are as follows: B6429);
(5) negative control: the healthy sheep blood serum for being uninfected by brucellosis;
(6) positive control: the sheep blood serum containing Brucella antibody;
(7) ELIAS secondary antibody: the anti-sheep IgG enzyme labelled antibody of the mouse of horseradish peroxidase-labeled;
(8) ELIAS secondary antibody dilution: Casein (SIGMA company, article No. are as follows: B6429);
(9) substrate developing solution: every 500mL adds disodium ethylene diamine tetraacetate 0.2g, citric acid 0.95g, glycerol 50mL and TMB
Powder 0.15g;
(10) terminate liquid: 2mol/L H2SO4Solution;
(11) cleaning solution: the phosphate buffer of 0.5 ‰ Tween-20 containing mass fraction, pH 7.4.
The foundation of the indirect ELISA method of 2.10 detection brucella
Using recombinant protein wzt of the invention as envelope antigen, 96 holes are coated with after being diluted to 15 μ g/mL with coating buffer
100 μ L are added in ELISA Plate, every hole, and 4 DEG C of coatings are overnight.It is washed 3 times with cleaning solution, each 2min is patted dry, and confining liquid is added, often
200 μ L are added in hole, in 37 DEG C of closing 3h.It is then washed 3 times with cleaning solution, each 2min.By serum to be checked (to serum to be checked
Type does not require, for example can be sheep, ox, pig, dog or human serum etc.), negative control and positive control use serum respectively
After dilution is diluted with volume ratio 1:80,100 μ L are added in every hole, and twice, i.e., multiple holes are loaded every part of serum sample-adding;Then 37
DEG C reaction 1h, washing pat dry for 3 times, every hole be added 100 μ L ELIAS secondary antibodies (use ELIAS secondary antibody diluted, extension rate 1:
5000) 37 DEG C of reaction 30min;It washs 3 times and pats dry.100 hole μ L/ of tmb substrate developing solution is added, 37 DEG C are protected from light 15min, so
2mol/L H is added with the amount in 50 holes μ L/ afterwards2SO4Reaction is terminated, enzyme mark detector measurement OD is set450Nm value.
The performance test of the brucella indirect ELISA testing kit of the invention of embodiment 2
The determination of 1.1 critical values
Taking 24 parts of negative sheep blood serums by extension rate is that 1:100 dilutes, and indirect ELISA is carried out under the optimum condition of screening
Measurement carries out statistical analysis to testing result, obtains OD450Average value (X) and standard deviation (SD).It will When, it is judged to the positive;When, it is judged to feminine gender.
10 24 parts of brucella negative serums of table
Result judgement: the condition for testing establishment is that Positive control wells are averaged OD450Value >=0.3 nm, negative control hole are average
OD450Nm value must < 0.3;As sample OD450Value >=0.3 nm, is judged to the positive;Sample OD450When nm value < 0.3, it is judged to feminine gender.
1.2 susceptibility results
11 sensitivity tests result of table
When P/N value is more than or equal to 2.0, corresponding serum diluting multiple is highest dilution, highest dilution 1:
1600。
1.3 specific
Yersinia enterocoltitica serum, Escherichia coli serum, three parts of brucella positive serums, three parts of brucella are taken respectively
Negative serum is detected according to the dilution screened with the indirect ELISA condition optimized, and every part of serum does 2 in parallel
A repetition, observes whether each serum and system have cross reaction, and test result is as shown in table 12.
12 specific test result of table
As shown in Table 12, with recombination wzt albumen coated elisa plate of the invention, positive control average value OD450Nm value is
0.844, negative control is averaged OD450Nm value is 0.266, with Yersinia enterocoltitica serum, Escherichia coli seroreaction, OD450nm
Value is respectively 0.179 and 0.101, lower than negative control.Illustrate that the kit has good specificity.
1.4 repeated
Repetitive test in batch:
5 parts of positive serums (being denoted as P1~P5) are taken to carry out indirect ELISA measurement, every part of serum under conditions of above-mentioned optimization
Sample does 10 repetitions in parallel, calculates the coefficient of variation (coefficient of variance, CV) as follows: CV=[sample
This OD450It is worth standard deviation (S)/sample OD450It is worth average] × 100%, test result is as shown in table 13.
13 batches, table interior repetitive test results
Test result is as shown in table 13, elisa plate is coated with the recombination wzt albumen of the invention of same a batch preparation, to 5 kinds
Sample is detected, and every kind of sample repeats 10 holes, and the coefficient of variation mean value that test is repeated in batch is 3.62%~5.35%, is lower than
10%, show that the ELISA detection method has repeatability in good batch.
Repetitive test between batch
The recombination wzt albumen coating of the invention for taking 3 parts of different batches, in the case where selecting optimal conditions to 5 kinds of serum into
The measurement of row indirect ELISA.Every kind of sample is repeated 3 times, and is averaged, and is observed its CV value with batch method of interior repetitive test, is tried
It is as shown in table 14 to test result.
14 batches of repetitive test results of table
Test result is shown in Table 14, is detected with the albumen of 3 different batches coating plate to 5 kinds of samples, every kind of serum weight
Again twice, the OD that 5 kinds of serum are measured in 3 batch elisa plates450The nm value coefficient of variation is 2.36%~4.59%, is lower than 10%,
Show repeated between the ELISA detection method has good batch.
Finally, it should be noted that the foregoing is only a preferred embodiment of the present invention, it is not intended to restrict the invention,
Although the present invention is described in detail referring to the foregoing embodiments, for those skilled in the art, still may be used
To modify the technical solutions described in the foregoing embodiments or equivalent replacement of some of the technical features.
All within the spirits and principles of the present invention, any modification, equivalent replacement, improvement and so on should be included in of the invention
Within protection scope.
Sequence table
<110>Lanzhou Veterinary Inst., Chinese Acedemy of Agaricultural Sciences
<120>a kind of brucella indirect ELISA testing kit
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 759
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 1
atgatccagc catcgattac cctgtcaaat gttcatctgc actacgctgc atcagcgttc 60
aaagaacgct cagtcaaaac tctagtaaac gccttattga gtatgcggcg cagcgcagga 120
gcaaacattg aagacatcca tgccctaaag ggtatttctg tagatatagc gcggggcgaa 180
cgcgttgccc tgataggtca caacggggct ggcaaaagta cgttcttgaa aactatagcc 240
ggtctctacc ctatatcatc tgggacatta aaagtgacgg gtaccgtaag atccctgttc 300
gatattggtc ttgggtttga gcctgatgca actggccgtg agaatattct ttaccgtggg 360
ttgcttctcg gactaacgcc acgtttcatg cgagagatcg aggatgagat catcgagttc 420
gcggatctcg gcgattttat cgattatcca atcaaaactt attctgccgg catgcaagtt 480
cggctcgcct tcgcgatttc gacagcagtc gacggcgaca tactccttct agacgaagtt 540
ataggtgcag gtgatgcggc attcatgact aaggcgaagg cccgcataat gaatatggtc 600
gagaaggctg agataatggt tctagcaagc catgaccttg cgaacgtccg tcagctttgc 660
acacgagcat tggttttcaa agccggcaca attgcatttg atggcagggt agaagacgcg 720
atttccttct ataactcggg aatgggagct atagcatga 759
<210> 2
<211> 252
<212> PRT
<213>artificial sequence (Artificial Sequence)
<400> 2
Met Ile Gln Pro Ser Ile Thr Leu Ser Asn Val His Leu His Tyr Ala
1 5 10 15
Ala Ser Ala Phe Lys Glu Arg Ser Val Lys Thr Leu Val Asn Ala Leu
20 25 30
Leu Ser Met Arg Arg Ser Ala Gly Ala Asn Ile Glu Asp Ile His Ala
35 40 45
Leu Lys Gly Ile Ser Val Asp Ile Ala Arg Gly Glu Arg Val Ala Leu
50 55 60
Ile Gly His Asn Gly Ala Gly Lys Ser Thr Phe Leu Lys Thr Ile Ala
65 70 75 80
Gly Leu Tyr Pro Ile Ser Ser Gly Thr Leu Lys Val Thr Gly Thr Val
85 90 95
Arg Ser Leu Phe Asp Ile Gly Leu Gly Phe Glu Pro Asp Ala Thr Gly
100 105 110
Arg Glu Asn Ile Leu Tyr Arg Gly Leu Leu Leu Gly Leu Thr Pro Arg
115 120 125
Phe Met Arg Glu Ile Glu Asp Glu Ile Ile Glu Phe Ala Asp Leu Gly
130 135 140
Asp Phe Ile Asp Tyr Pro Ile Lys Thr Tyr Ser Ala Gly Met Gln Val
145 150 155 160
Arg Leu Ala Phe Ala Ile Ser Thr Ala Val Asp Gly Asp Ile Leu Leu
165 170 175
Leu Asp Glu Val Ile Gly Ala Gly Asp Ala Ala Phe Met Thr Lys Ala
180 185 190
Lys Ala Arg Ile Met Asn Met Val Glu Lys Ala Glu Ile Met Val Leu
195 200 205
Ala Ser His Asp Leu Ala Asn Val Arg Gln Leu Cys Thr Arg Ala Leu
210 215 220
Val Phe Lys Ala Gly Thr Ile Ala Phe Asp Gly Arg Val Glu Asp Ala
225 230 235 240
Ile Ser Phe Tyr Asn Ser Gly Met Gly Ala Ile Ala
245 250
Claims (9)
1. a kind of brucella indirect ELISA testing kit, it is characterised in that: the kit is with brucella wzt recombination
Albumen is envelope antigen.
2. a kind of brucella indirect ELISA testing kit according to claim 1, it is characterised in that: the recombination
The amino acid sequence of albumen is SEQ ID No.2 in sequence table.
3. a kind of brucella indirect ELISA testing kit according to claim 1, it is characterised in that: the recombination
Albumen the preparation method comprises the following steps: by the multiple cloning sites of brucella wzt gene fragment clone to pET30a (+) expression vector,
Obtain recombinant plasmid pET-30a-wzt, by recombinant plasmid pET-30a-wzt be transformed into e. coli bl21 competent cell into
Row inducing expression is collected supernatant and is purified, obtains recombinant protein after purification.
4. a kind of brucella indirect ELISA testing kit according to claim 1, it is characterised in that: the reagent
Box further includes confining liquid, and the confining liquid is Casein.
5. a kind of brucella indirect ELISA testing kit according to claim 1, it is characterised in that: the reagent
Box further includes coating buffer, the carbonate buffer solution that the coating buffer is 0.025M pH9.6.
6. a kind of brucella indirect ELISA testing kit according to claim 1, it is characterised in that: the reagent
Box further includes serum dilution, and the serum dilution is Casein.
7. a kind of brucella indirect ELISA testing kit according to claim 1, it is characterised in that: the reagent
Box further includes ELIAS secondary antibody, and the ELIAS secondary antibody is the anti-sheep IgG enzyme labelled antibody of mouse of horseradish peroxidase-labeled.
8. application of the described in any item kits of claim 1-7 in detection brucella, the application is not with disease
For the purpose of diagnosing and treating.
9. the indirect ELISA detection method of brucella, the detection method is special not for the purpose of the diagnosing and treating of disease
Sign is: steps are as follows:
(1) coated elisa plate: pET-30a-wzt recombinant protein described in claim any one of 1-3 after purification is coated with
Microwell plate;Peridium concentration is 15 μ g/mL;Coating condition is that 4 DEG C of coatings are stayed overnight;
(2) ELISA Plate is closed;The confining liquid being closed as when 37 DEG C of closing 3h, closing is Casein;
(3) serum to be checked after dilution is added, in 37 DEG C of reaction 1h;It is described to be diluted to serum serum dilution to be checked with 1:
80 are diluted;
(4) ELIAS secondary antibody after dilution is added, in 37 DEG C of reaction 30min or 90min;It is described to be diluted to ELIAS secondary antibody enzyme mark
Secondary antibody diluent is diluted with 1:5000;
(5) it develops the color, terminates, and read OD in microplate reader450Nm value.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811301269.8A CN109142757A (en) | 2018-11-02 | 2018-11-02 | A kind of brucella indirect ELISA testing kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811301269.8A CN109142757A (en) | 2018-11-02 | 2018-11-02 | A kind of brucella indirect ELISA testing kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109142757A true CN109142757A (en) | 2019-01-04 |
Family
ID=64807517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811301269.8A Pending CN109142757A (en) | 2018-11-02 | 2018-11-02 | A kind of brucella indirect ELISA testing kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109142757A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113122453A (en) * | 2021-04-16 | 2021-07-16 | 青海省地方病预防控制所 | Culture medium for separating brucella in woodchuck tissue and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101386831A (en) * | 2008-10-22 | 2009-03-18 | 中国农业大学 | A recombinant bacterium of Brucella abortus with immune marker and its application |
| CN101386830A (en) * | 2008-10-22 | 2009-03-18 | 中国农业大学 | A recombinant bacterium of Brucella melis with immune marker and its application |
| CN102665739A (en) * | 2009-09-21 | 2012-09-12 | 国家医疗保健研究所 | Modified gram-negative bacteria for use as vaccines |
| CN103344770A (en) * | 2013-07-15 | 2013-10-09 | 山东省农业科学院奶牛研究中心 | Brucella abortus indirect enzyme linked immunosorbent assay (ELISA) detection kit |
| WO2014157611A1 (en) * | 2013-03-28 | 2014-10-02 | 国立大学法人宮崎大学 | Method for detecting wide-range of e. coli o-serogroups using pcr |
| US20170080080A1 (en) * | 2014-05-19 | 2017-03-23 | Board Of Regents, The University Of Texas System | Combinatorial platform for the display of surface adjuvants and antigens |
| CN107236039A (en) * | 2017-07-17 | 2017-10-10 | 吉林农业大学 | Recombinate Wzt albumen rabbit anteserum polyclonal antibodies and preparation method thereof |
-
2018
- 2018-11-02 CN CN201811301269.8A patent/CN109142757A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101386831A (en) * | 2008-10-22 | 2009-03-18 | 中国农业大学 | A recombinant bacterium of Brucella abortus with immune marker and its application |
| CN101386830A (en) * | 2008-10-22 | 2009-03-18 | 中国农业大学 | A recombinant bacterium of Brucella melis with immune marker and its application |
| CN102665739A (en) * | 2009-09-21 | 2012-09-12 | 国家医疗保健研究所 | Modified gram-negative bacteria for use as vaccines |
| WO2014157611A1 (en) * | 2013-03-28 | 2014-10-02 | 国立大学法人宮崎大学 | Method for detecting wide-range of e. coli o-serogroups using pcr |
| CN103344770A (en) * | 2013-07-15 | 2013-10-09 | 山东省农业科学院奶牛研究中心 | Brucella abortus indirect enzyme linked immunosorbent assay (ELISA) detection kit |
| US20170080080A1 (en) * | 2014-05-19 | 2017-03-23 | Board Of Regents, The University Of Texas System | Combinatorial platform for the display of surface adjuvants and antigens |
| CN107236039A (en) * | 2017-07-17 | 2017-10-10 | 吉林农业大学 | Recombinate Wzt albumen rabbit anteserum polyclonal antibodies and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 庞峰 等。: "羊种布鲁氏菌Wzt基因的克隆及原核表达", 《中国畜牧兽医》 * |
| 王浩。: "布鲁氏菌Wzt蛋白的表达及相关性质研究。", 《中国优秀硕士学位论文全文数据库 农业科技辑》 * |
| 王秀然。: "布鲁氏菌wzm/wzt基因对其毒力、免疫原性及蛋白质表达影响的研究。", 《中国博士学位论文全文数据库 农业科技辑》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113122453A (en) * | 2021-04-16 | 2021-07-16 | 青海省地方病预防控制所 | Culture medium for separating brucella in woodchuck tissue and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109655621B (en) | Indirect ELISA antibody detection method for swine T-type coronavirus N protein and kit thereof | |
| CN111929433A (en) | African swine fever virus antibody ELISA detection kit and preparation method thereof | |
| CN110376384A (en) | The ELISA detection kit of bee honey and Apis mellifera honey in detection | |
| Chen et al. | Application of an AlphaLISA method for rapid sensitive detection of African swine fever virus in porcine serum | |
| CN112639118A (en) | Method for enhancing sensitivity of endotoxin-assaying agent | |
| CN113563479A (en) | Kit for diagnosing echinococcosis | |
| CN112415195A (en) | Kit for detecting dual targets of novel coronavirus and its application | |
| CN109142757A (en) | A kind of brucella indirect ELISA testing kit | |
| Ning et al. | Development of an enzyme-linked phage receptor-binding protein assay (ELPRA) based on a novel biorecognition molecule-receptor-binding protein Gp130 of Pseudomonas aeruginosa bacteriophage Henu5 | |
| CN117603366B (en) | Brucella specific fusion antigen and application thereof | |
| CN104155443A (en) | Indirect ELISA (enzyme-linked immunosorbent assay) detection kit based on toxoplasma gondii matrix protein 1 | |
| US12158469B2 (en) | Synthetic peptide for detecting HIV-1 | |
| CN109917032B (en) | Quantitative detection method for Bt protein in Bt protein-transgenic food | |
| Liu et al. | Development of recombinant antigen array for simultaneous detection of viral antibodies | |
| KR102266295B1 (en) | Interfering peptides and method for detecting micro-organisms | |
| CN114539362B (en) | A botulinum toxin-specific substrate peptide, detection kit and detection method | |
| CN105866421A (en) | Bovine theileria annulata indirect ELISA antibody detection kit and preparation method thereof | |
| WO2024204714A1 (en) | Reagent, kit, and method for detecting substance to be measured | |
| CN114720691B (en) | Kit for detecting biomarkers and preparation method and application thereof | |
| CN113447656B (en) | Kit for detecting anti-filamentous actin cap-forming protein beta-IgG antibody | |
| JP7523129B2 (en) | Method and kit for identifying Helicobacter pylori strains | |
| CN112444626B (en) | African swine fever virus antibody ELISA detection kit and preparation method thereof | |
| Nuyttens et al. | Identification, expression and serological evaluation of the recombinant ATP synthase beta subunit of Mycoplasma pneumoniae | |
| WO2022115964A1 (en) | System and method for rapid and sensitive detection of anti-pathogen antibodies | |
| CN120004992B (en) | Antigen epitope polypeptide for detecting antibodies produced by Brucella infection and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190104 |
|
| RJ01 | Rejection of invention patent application after publication |